DSpace Repository

Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction

Show simple item record

dc.contributor.author Cerik, Idris Bugra
dc.contributor.author Dereli, Seckin
dc.contributor.author Kaya, Ahmet
dc.contributor.author Kilincel, Oguzhan
dc.date.accessioned 2022-08-17T05:32:09Z
dc.date.available 2022-08-17T05:32:09Z
dc.date.issued 2020
dc.identifier.uri http://doi.org/10.1080/00015385.2020.1730577
dc.identifier.uri http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2316
dc.description.abstract Background: In patients with heart failure (HF), depression and anxiety disorders are common and associated with adverse outcomes. Sacubitril/valsartan, which is an angiotensin receptor neprilysin inhibitor (ARNI), has been shown to reduce mortality and hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF). However, its effects on depression and anxiety levels remain unclear. Methods: Sacubitril/valsartan was initiated in 115 symptomatic patients with HFrEF receiving an optimal medical treatment with angiotensin inhibition. Patients underwent 6-minute walk test (6-MWT), The Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI) were administered at the switching to ARNI and at the third-month follow-up of the maximum sacubitril/valsartan dose. Results: A significant improvement was observed in BDI-II and BAI scores when compared before and after the sacubitril/valsartan treatment (13.7 +/- 9.7 to 7.6 +/- 3.8, p < 0.001 and 13.3 +/- 8.9 to 8.1 +/- 4.1, p < 0.001, respectively). The 6-MWT distance significantly increased from 213 +/- 95 to 327 +/- 118 mt (p < 0.001). Overall, the patients exhibited a significant functional improvement following the initiation of sacubitril/valsartan: 27% of the patients improved by two New York Heart Association (NYHA) classes, 52% improved by one NYHA functional class, and 31% remained stable. Conclusion: In patients with HFrEF, the switch from angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to sacubitril/valsartan resulted in a significant improvement in both depression, anxiety symptoms and functional statuses. en_US
dc.language.iso eng en_US
dc.publisher TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND en_US
dc.relation.isversionof 10.1080/00015385.2020.1730577 en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject LCZ696 SACUBITRIL/VALSARTAN; RATE-VARIABILITY; HEALTH-STATUS; WALK TEST; MORTALITY; INVENTORY; DISORDER; ASSOCIATIONS; INFLAMMATION; INHIBITION en_US
dc.subject Sacubitril; valsartan; heart failure; depression; anxiety en_US
dc.title Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction en_US
dc.type article en_US
dc.relation.journal ACTA CARDIOLOGICA en_US
dc.contributor.department Ordu Üniversitesi en_US
dc.contributor.authorID 0000-0001-9845-7938 en_US
dc.contributor.authorID 0000-0003-0090-3835 en_US
dc.contributor.authorID 0000-0003-1419-3950 en_US
dc.contributor.authorID 0000-0003-2988-4631 en_US
dc.identifier.volume 75 en_US
dc.identifier.issue 8 en_US
dc.identifier.startpage 774 en_US
dc.identifier.endpage 782 en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account